Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:NUVL

Nuvalent Q1 2025 Earnings Report

Nuvalent logo
$101.47 -1.15 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$101.45 -0.02 (-0.02%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nuvalent EPS Results

Actual EPS
-$1.18
Consensus EPS
-$1.14
Beat/Miss
Missed by -$0.04
One Year Ago EPS
-$0.69

Nuvalent Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvalent Announcement Details

Quarter
Q1 2025
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Nuvalent's Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Nuvalent's Q1 2025 Press ReleasePress Release
(8-K)
Nuvalent's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Nuvalent Earnings Headlines

Deborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) Stock
May 3 at 4:49 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30755791
Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC
May 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/nuvalent-nuvl-submits-nda-fda-101130677.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 5 at 1:00 AM  |  Profits Run (Ad)
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4896874-nuvalent-a-precision-oncology-platform-with-two-near-term-shots-on-goal
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
April 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260430014027/en/guardant-health-announces-multi-year-strategic-collaboration-with-nuvalent-to-develop-companion-diagnostics-and-support-potential-commercialization-of-targeted-cancer-therapies-using-the-guardant-infinity%e2%84%a2-platform/
Canaccord Genuity Remains a Buy on Nuvalent (NUVL)
April 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NUVL/pressreleases/1498315/canaccord-genuity-remains-a-buy-on-nuvalent-nuvl/
See More Nuvalent Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvalent? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvalent and other key companies, straight to your email.

About Nuvalent

Nuvalent (NASDAQ:NUVL) (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations. These assets are being evaluated in multicenter Phase 1/2 clinical trials across the United States and Europe, with early data demonstrating favorable safety profiles and preliminary signs of clinical activity in patients with RET-driven and KRAS-mutant solid tumors. In addition to these core programs, Nuvalent continues to leverage its structure-based approach to advance discovery efforts and expand its portfolio into other oncogenic targets.

The company conducts its operations primarily in North America, supported by strategic collaborations and investigator-led studies in international research centers. Under the leadership of President and Chief Executive Officer Bill Haney, Nuvalent has assembled a management team with extensive experience in oncology drug development, regulatory affairs and commercial planning. The organization remains committed to translating cutting-edge science into precision medicines that address unmet needs in cancer therapy.

View Nuvalent Profile
Earnings Tools